| __timestamp | Celldex Therapeutics, Inc. | Merus N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 20622000 | 3852327 |
| Thursday, January 1, 2015 | 33837000 | 839656 |
| Friday, January 1, 2016 | 35979000 | 4478145 |
| Sunday, January 1, 2017 | 25003000 | 16432324 |
| Monday, January 1, 2018 | 19269000 | 11890871 |
| Tuesday, January 1, 2019 | 15426000 | 34110000 |
| Wednesday, January 1, 2020 | 14456000 | 35781000 |
| Friday, January 1, 2021 | 20488000 | 40896000 |
| Saturday, January 1, 2022 | 27195000 | 52200000 |
| Sunday, January 1, 2023 | 30914000 | 59836000 |
Unleashing insights
In the competitive landscape of biotechnology, operational efficiency is paramount. Over the past decade, Merus N.V. and Celldex Therapeutics, Inc. have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Celldex's SG&A expenses have seen a steady increase, peaking at approximately 31 million in 2023, a 50% rise from 2014. In contrast, Merus N.V. has experienced a more dramatic escalation, with expenses surging from under 1 million in 2015 to nearly 60 million in 2023, marking a staggering 7000% increase. This divergence highlights differing strategic priorities and growth trajectories. As these companies continue to innovate, understanding their financial strategies offers valuable insights into their operational dynamics and market positioning.
Comparing SG&A Expenses: Eli Lilly and Company vs Merus N.V. Trends and Insights
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Celldex Therapeutics, Inc.
Breaking Down SG&A Expenses: Amgen Inc. vs Merus N.V.
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Merus N.V.
Comparing SG&A Expenses: Genmab A/S vs Merus N.V. Trends and Insights
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Merus N.V.
SG&A Efficiency Analysis: Comparing Walgreens Boots Alliance, Inc. and Merus N.V.
Operational Costs Compared: SG&A Analysis of Exelixis, Inc. and Merus N.V.
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Celldex Therapeutics, Inc.
Veracyte, Inc. vs Merus N.V.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Merus N.V. or Galapagos NV
Arrowhead Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends